Geron (GERN) Stock: Buy, Sell, or Hold?
$1.02
+0.05 (+4.70%)
▲
5d:
-5.56%
30d:
-15.0%
90d:
-33.55%
Open in Live Scanner
70/30 Portfolio Builder
Earnings: Nov 04, 2026
0d
Protect GERN Gains
Updated Nov 11, 12:00 AM ET
QUANTITATIVE VERDICT
HOLD
LOW Confidence (95%)
Quality Score
63/100
Position
SLIGHTLY LOW
30-Day Fair Range
$0.99 – $1.22
Position: SLIGHTLY LOW
Forward P/E & Valuation
11.3x
CHEAP
vs 24.7x historical avg
Wall Street Target
$3.50
+243.1% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$0.86 / $1.09
Trend: Strong Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 HOLD: GERN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Get Alerted When GERN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: GERN is currently trading at $1.02, which is considered slightly low relative to its 30-day fair value range of $0.99 to $1.22. From a valuation perspective, the stock is trading at a discount (Forward PE: 11.3) compared to its historical average (24.7). Remarkably, the market is currently pricing in an annual earnings decline of 22.9% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, GERN is in a strong downtrend. Immediate support is located at $0.86, while resistance sits at $1.09. The stock is showing strong short-term momentum, up 4.7% recently.
Market Sentiment: GERN scores 93/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $3.50 (+243.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, GERN is in a strong downtrend. Immediate support is located at $0.86, while resistance sits at $1.09. The stock is showing strong short-term momentum, up 4.7% recently.
Market Sentiment: GERN scores 93/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $3.50 (+243.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$0.99 -
$1.22
Company Quality Score
63/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
95.2%
Trading Range & Key Levels
30-Day Trading Range
$0.99 -
$1.22
Current vs Trading Range
SLIGHTLY LOW
Support Level
$0.86
Resistance Level
$1.09
Current Trend
Strong Downtrend
Technical data as of
Nov 11, 2026
Protect Your Profits
Holding GERN? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanQuantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (93/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.7%)
- BULLISH: Trading 243.1% below Wall St target ($3.50)
- BULLISH: Bottoming setup score 93/100 — corrected, stabilizing, and turning up
- CAUTION: Recommendation downgraded due to -5.6% 5-day decline
Fundamental Context
Forward P/E (Next Year Est.)
11.33
Wall Street Target
$3.50
(+243.1%)
Revenue Growth (YoY)
27.4%
Profit Margin
-22.0%
Valuation Discount vs History
-22.9% cheaper
PE vs Historical
11.3 vs 24.7
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-22.9%
(market-implied from PE analysis)
1-Year Target
$0.92
(-10%)
2-Year Target
$0.83
(-19%)
3-Year Target
$0.74
(-27%)
3-Yr Target (if PE normalizes)
(PE: 11→25)
$1.62
(+59%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 11.3 to 24.7
Stabilization Target:
$2.22
(+117.9%)
PE Expansion Potential:
+117.9%
Share GERN Analysis
Share this live GERN analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (GERN)
Bullish
2 Retail Mentions
Reddit / WSB Comments
1
Bearish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 11, 2026
Daily AI digest
AI Retail Discussion Summary:
Geron is focusing on expanding the use of its blood cancer drug RYTELO in Germany and community practices in the U.S., with recent growth and a goal of reaching the middle to high end of its annual revenue guidance.
Key Retail Themes:
Expansion into Germany and community practices
Revenue growth and guidance
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 3:09 AM ET
Data refreshes hourly during market hours. Next update: 4:09 AM
Data refreshes hourly during market hours. Next update: 4:09 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GERN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
22 analysts |
$107 | 61 BUY |
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$194 | 37 SELL |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
19 analysts |
$689 | 56 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
|
RCUS
Arcus Biosciences Inc |
STRONG BUY
15 analysts |
$41 | 63 BUY |
Advanced GERN Option Strategies
Professional options setups generated by AI based on today's GERN price and gamma walls.
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive GERN Research Pages
